𝔖 Bobbio Scriptorium

✦ LIBER ✦

Pertuzumab may add benefit to gemcitabine in epithelial ovarian cancer

Book ID: 120846533
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2007
Weight: 133 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200716120-00029

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gemcitabine associated vasculitis leadin

Gemcitabine associated vasculitis leading to necrotizing enterocolitis and death in women undergoing primary treatment for epithelial ovarian/peritoneal cancer

✍ John P Geisler; Daniel F Schraith; Kelly J Manahan; Joel I Sorosky 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 202 KB

5002 ORAL Results from a Phase II random

5002 ORAL Results from a Phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer

✍ Makhija, S.; Glenn, D.; Ueland, F.; Dizon, D.; Paton, V.; Lin, C.Y.; Amler, L.; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 77 KB

Late-Breaking Abstract 5: Results from a

Late-Breaking Abstract 5: Results from a 2nd interim OS analysis in OCEANS: A randomized phase 3 trial of gemcitabine (G), carboplatin (C) and bevacizumab (BV) followed by BV to disease progression in patients with platinum-sensitive recurrent epithelial ovarian (OC), primary peritoneal (PPC), or fallopian tube cancer (FTC)

✍ C. Aghajanian; S. Blank; B. Goff; P. Judson; L. Nycum; M. Sovak; J. Yi; A. Husai 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 42 KB